Guarini et al. demonstrated that CD19-directed CAR T cell treatment of DLBCL and ALL patients induces a reshaping of the immune system by increasing T cell counts and inducing cytokine production [20]. Here, CD19 is linked to diffuse large B-cell lymphoma.